FDA Considering "Numerous" Ephedra Adverse Events In Rulemaking
This article was originally published in The Tan Sheet
Executive Summary
FDA will take the "numerous adverse events" related to ephedra that continue to be reported to the agency into consideration as it develops rulemaking on the substance, FDA Commissioner Jane Henney, MD, said at a budget hearing of the House Agriculture Appropriations subcommittee Feb. 23.